ijms-logo

Journal Browser

Journal Browser

New Advances in Nanomedicine Innovation in Cancer Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 1117

Special Issue Editor


E-Mail
Guest Editor
Nanomedicine Lab, University of Franche-Comté, 16 route de Gray, 25030 Besançon, France
Interests: nanotechnology; nanomedicine; radiotherapy; theragnostic; antibody-drug-conjugates (ADCs); drug delivery; radiopharmaceutical; gold nanoparticles; nanoparticle–biomolecule conjugate

Special Issue Information

Dear Colleagues,

Concerning the transformative potential of nanotechnology in revolutionizing cancer treatment, the convergence of nanomedicine, radiotherapy, and theragnostics is at the forefront of this revolution, offering unprecedented improvements in therapeutic efficacy and patient outcomes. Key topics include the development of targeted therapies using antibody–drug conjugates (ADCs) and innovative drug delivery systems. Nanoparticle–biomolecule conjugates, such as gold nanoparticles, are highlighted for their role in enhancing the precision of radiopharmaceuticals and improving the targeting of cancer cells. Integrating nanotechnology with traditional cancer treatments aims to provide real-time imaging and theragnostic capabilities, allowing for more accurate monitoring and adjustment of therapies. The issue also investigates the latest advancements in nanomedicine, focusing on how these technologies address unmet medical needs by offering more effective and less invasive treatment options. The combined use of radiotherapy and nanotechnology examines the potential for significantly improving the quality of life of cancer patients, showcasing how these innovative approaches can lead to better outcomes and more personalized treatment plans. This Special Issue provides a comprehensive overview of how innovative nanotechnology is shaping the future of cancer therapy, highlighting the critical advancements and their implications for clinical practice.

Prof. Dr. Tijani Gharbi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • nanomedicine
  • radiotherapy
  • theragnostic
  • antibody–drug conjugates (ADCs)
  • drug delivery
  • radiopharmaceutical
  • gold nanoparticles
  • nanoparticle–biomolecule conjugate

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3006 KiB  
Article
Au@109Pd Core–Shell Nanoparticles Conjugated to Panitumumab for the Combined β—Auger Electron Therapy of Triple-Negative Breast Cancer
by Nasrin Abbasi Gharibkandi, Agnieszka Majkowska-Pilip, Rafał Walczak, Mateusz Wierzbicki and Aleksander Bilewicz
Int. J. Mol. Sci. 2024, 25(24), 13555; https://doi.org/10.3390/ijms252413555 - 18 Dec 2024
Viewed by 586
Abstract
Apart from HER2-positive, triple-negative breast cancer (TNBC) is the second most highly invasive type of breast cancer. Although TNBC does not overexpress HER2 receptors, it has been observed that EGFR protein expression is present in this specific type of tumor, making it an [...] Read more.
Apart from HER2-positive, triple-negative breast cancer (TNBC) is the second most highly invasive type of breast cancer. Although TNBC does not overexpress HER2 receptors, it has been observed that EGFR protein expression is present in this specific type of tumor, making it an attractive target for immune and radiopharmaceutical treatments. In our current study, we used 109Pd (T1/2 = 13.7 h) in the form of a 109Pd/109mAg in vivo generator as a source of β particles and Auger electrons in targeted radionuclide therapy for TNBC. 109Pd, obtained through neutron irradiation of the 108Pd target, was deposited onto 15 nm gold nanoparticles to form Au@109Pd core–shell nanoparticles, which were then conjugated to the panitumumab antibody. Au@109Pd-PEG-panitumumab nanoparticles were bound, internalized, and partially routed to the nucleus in MDA-MB-231 human breast cancer cells overexpressing EGFR receptors. The Au@109Pd-panitumumab radioconjugate significantly reduced the metabolic activity of MDA-MB-231 cells in a dose-dependent manner. In conclusion, we have found that Au@109Pd-PEG-panitumumab nanoparticles show potential as a therapeutic agent for combined β–Auger electron targeted radionuclide therapy of TNBC. The simultaneous emission of β, conversion, and Auger electrons from the 109Pd/109mAg generator, similar to 161Tb conjugates, significantly enhances the therapeutic effect. The partial localization of these nanoparticles into the cell nucleus, provided by the panitumumab vector, ensures effective therapy with Auger electrons. This is particularly important for the treatment of drug-resistant TNBC cells. Full article
(This article belongs to the Special Issue New Advances in Nanomedicine Innovation in Cancer Treatment)
Show Figures

Figure 1

Back to TopTop